Download PDF
Semin Respir Crit Care Med 2017; 38(04): 477-498
DOI: 10.1055/s-0037-1602381
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Cardiac Involvement in Sarcoidosis: Evolving Concepts in Diagnosis and Treatment

David M. Sayah
1   Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Jason S. Bradfield
2   Division of Cardiology, Department of Medicine, UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine at UCLA, Los Angeles, California
,
John M. Moriarty
3   Division of Interventional Radiology, Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, California
,
John A. Belperio
1   Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Joseph P. Lynch III
1   Division of Pulmonary and Critical Care Medicine, Clinical Immunology, and Allergy, David Geffen School of Medicine at UCLA, Los Angeles, California
› Author Affiliations
Further Information

Publication History

Publication Date:
27 July 2017 (online)

    Permissions and Reprints

Abstract

Clinically evident sarcoidosis involving the heart has been noted in at least 2 to 7% of patients with sarcoidosis, but occult involvement is much higher (> 20%). Cardiac sarcoidosis is often not recognized antemortem, as sudden death may be the presenting feature. Cardiac involvement may occur at any point during the course of sarcoidosis and may occur in the absence of pulmonary or systemic involvement. Sarcoidosis can involve any part of the heart, with protean manifestations. Prognosis of cardiac sarcoidosis is related to the extent and site(s) of involvement. Most deaths due to cardiac sarcoidosis are due to arrhythmias or conduction defects, but granulomatous infiltration of the myocardium may be lethal. The definitive diagnosis of isolated cardiac sarcoidosis is difficult. The yield of endomyocardial biopsies is low; treatment of cardiac sarcoidosis is often warranted even in the absence of histologic proof. Radionuclide scans are integral to the diagnosis. Currently, 18F-fluorodeoxyglucose–positron emission tomography/computed tomography and gadolinium-enhanced magnetic resonance imaging scans are the key imaging modalities to diagnose cardiac sarcoidosis. The prognosis of cardiac sarcoidosis is variable, but mortality rates of untreated cardiac sarcoidosis are high. Although randomized therapeutic trials have not been done, corticosteroids (alone or combined with additional immunosuppressive medications) remain the mainstay of treatment. Because of the potential for sudden cardiac death, implantable cardioverter defibrillators should be placed in any patient with cardiac sarcoidosis and serious ventricular arrhythmias or heart block, and should be considered for cardiomyopathy. Cardiac transplantation is a viable option for patients with end-stage cardiac sarcoidosis refractory to medical therapy.

Keywords

sarcoidosis - cardiac - ventricular arrhythmias - cardiomyopathy - implantable cardioverter defibrillators
 

  • References

  • 1 Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357 (21) 2153-2165
    CrossrefPubMedGoogle Scholar
  • 2 Fleming H. Cardiac sarcoidosis. In: James DG. , ed. Sarcoidosis and Other Granulomatous Disorders. New York: Marcel Dekker; 1994: 323-334
    Google Scholar
  • 3 Fleming HA. Sarcoid heart disease. Br Heart J 1974; 36 (01) 54-68
    CrossrefPubMedGoogle Scholar
  • 4 Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160 (02) 736-755
    CrossrefPubMedGoogle Scholar
  • 5 Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999; 78 (02) 65-111
    CrossrefPubMedGoogle Scholar
  • 6 Ayyala US, Nair AP, Padilla ML. Cardiac sarcoidosis. Clin Chest Med 2008; 29 (03) 493-508 , ix
    CrossrefPubMedGoogle Scholar
  • 7 Baughman RP, Teirstein AS, Judson MA. , et al; A Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10 Pt 1): 1885-1889
    CrossrefPubMedGoogle Scholar
  • 8 Nunes H, Freynet O, Naggara N. , et al. Cardiac sarcoidosis. Semin Respir Crit Care Med 2010; 31 (04) 428-441
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Kandolin R, Lehtonen J, Airaksinen J. , et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015; 131 (07) 624-632
    CrossrefPubMedGoogle Scholar
  • 10 Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest 2017; 151 (01) 139-148
    CrossrefPubMedGoogle Scholar
  • 11 Kinney EL, Jackson GL, Reeves WC, Zelis R. Thallium-scan myocardial defects and echocardiographic abnormalities in patients with sarcoidosis without clinical cardiac dysfunction. An analysis of 44 patients. Am J Med 1980; 68 (04) 497-503
    CrossrefPubMedGoogle Scholar
  • 12 Tellier P, Paycha F, Antony I. , et al. Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. Am J Med 1988; 85 (02) 189-193
    CrossrefPubMedGoogle Scholar
  • 13 Fahy GJ, Marwick T, McCreery CJ, Quigley PJ, Maurer BJ. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996; 109 (01) 62-66
    CrossrefPubMedGoogle Scholar
  • 14 Bulkley BH, Rouleau JR, Whitaker JQ, Strauss HW, Pitt B. The use of 201thallium for myocardial perfusion imaging in sarcoid heart disease. Chest 1977; 72 (01) 27-32
    PubMedGoogle Scholar
  • 15 Burstow DJ, Tajik AJ, Bailey KR, DeRemee RA, Taliercio CP. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 1989; 63 (07) 478-482
    CrossrefPubMedGoogle Scholar
  • 16 Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol 2016; 68 (04) 411-421
    CrossrefPubMedGoogle Scholar
  • 17 Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995; 119 (02) 167-172
    PubMedGoogle Scholar
  • 18 Roberts WC, McAllister Jr HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977; 63 (01) 86-108
    CrossrefPubMedGoogle Scholar
  • 19 Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58 (06) 1204-1211
    CrossrefPubMedGoogle Scholar
  • 20 Virmani R, Bures JC, Roberts WC. Cardiac sarcoidosis; a major cause of sudden death in young individuals. Chest 1980; 77 (03) 423-428
    CrossrefPubMedGoogle Scholar
  • 21 Bagwan IN, Hooper LV, Sheppard MN. Cardiac sarcoidosis and sudden death. The heart may look normal or mimic other cardiomyopathies. Virchows Arch 2011; 458 (06) 671-678
    CrossrefPubMedGoogle Scholar
  • 22 Matsui Y, Iwai K, Tachibana T. , et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 1976; 278: 455-469
    CrossrefPubMedGoogle Scholar
  • 23 Segura AM, Radovancevic R, Demirozu ZT, Frazier OH, Buja LM. Granulomatous myocarditis in severe heart failure patients undergoing implantation of a left ventricular assist device. Cardiovasc Pathol 2014; 23 (01) 17-20
    CrossrefPubMedGoogle Scholar
  • 24 Nery PB, Mc Ardle BA, Redpath CJ. , et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 2014; 37 (03) 364-374
    CrossrefPubMedGoogle Scholar
  • 25 Sperry BW, Oldan J, Hachamovitch R, Tamarappoo BK. Insights into biopsy-proven cardiac sarcoidosis in patients with heart failure. J Heart Lung Transplant 2016; 35 (03) 392-393
    CrossrefPubMedGoogle Scholar
  • 26 Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012; 141 (01) 154-162
    CrossrefPubMedGoogle Scholar
  • 27 Judson MA, Costabel U, Drent M. , et al. The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (01) 19-27
    PubMedGoogle Scholar
  • 28 Birnie DH, Sauer WH, Bogun F. , et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11 (07) 1305-1323
    CrossrefPubMedGoogle Scholar
  • 29 Lynch III JP, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med 2014; 35 (03) 372-390
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993; 103 (01) 253-258
    CrossrefPubMedGoogle Scholar
  • 31 Longcope WT, Freiman DG. A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital. Medicine (Baltimore) 1952; 31 (01) 1-132
    CrossrefPubMedGoogle Scholar
  • 32 Yazaki Y, Isobe M, Hiramitsu S. , et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 1998; 82 (04) 537-540
    CrossrefPubMedGoogle Scholar
  • 33 Yazaki Y, Isobe M, Hiroe M. , et al; Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88 (09) 1006-1010
    CrossrefPubMedGoogle Scholar
  • 34 Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 1996; 10 (05) 495-510
    CrossrefPubMedGoogle Scholar
  • 35 Iwai K, Sekiguti M, Hosoda Y. , et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994; 11 (01) 26-31
    PubMedGoogle Scholar
  • 36 Sekiguchi M, Numao Y, Imai M, Furuie T, Mikami R. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis. Jpn Circ J 1980; 44 (04) 249-263
    CrossrefPubMedGoogle Scholar
  • 37 Tachibana T, Ohmori F, Ueda E. Clinical study on cardiac sarcoidosis. Ann N Y Acad Sci 1986; 465: 530-542
    CrossrefPubMedGoogle Scholar
  • 38 Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med 1996; 100 (04) 423-427
    CrossrefPubMedGoogle Scholar
  • 39 Morimoto T, Azuma A, Abe S. , et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008; 31 (02) 372-379
    CrossrefPubMedGoogle Scholar
  • 40 Iannuzzi MC. Genetics of sarcoidosis. Semin Respir Crit Care Med 2007; 28 (01) 15-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Grunewald J. Review: role of genetics in susceptibility and outcome of sarcoidosis. Semin Respir Crit Care Med 2010; 31 (04) 380-389
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Fischer A, Grunewald J, Spagnolo P, Nebel A, Schreiber S, Müller-Quernheim J. Genetics of sarcoidosis. Semin Respir Crit Care Med 2014; 35 (03) 296-306
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Lagana SM, Parwani AV, Nichols LC. Cardiac sarcoidosis: a pathology-focused review. Arch Pathol Lab Med 2010; 134 (07) 1039-1046
    PubMedGoogle Scholar
  • 44 Chapelon-Abric C, de Zuttere D, Duhaut P. , et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 2004; 83 (06) 315-334
    CrossrefPubMedGoogle Scholar
  • 45 Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol 2009; 104 (04) 571-577
    CrossrefPubMedGoogle Scholar
  • 46 Stewart RE, Graham DM, Godfrey GW, Friedman HZ, Das SK, Shea MJ. Rapidly progressive heart failure resulting from cardiac sarcoidosis. Am Heart J 1988; 115 (06) 1324-1326
    CrossrefPubMedGoogle Scholar
  • 47 Shammas RL, Movahed A. Sarcoidosis of the heart. Clin Cardiol 1993; 16 (06) 462-472
    CrossrefPubMedGoogle Scholar
  • 48 Fleming HA, Bailey SM. Sarcoid heart disease. J R Coll Physicians Lond 1981; 15 (04) 245-246 , 249–253
    PubMedGoogle Scholar
  • 49 Kim JS, Judson MA, Donnino R. , et al. Cardiac sarcoidosis. Am Heart J 2009; 157 (01) 9-21
    CrossrefPubMedGoogle Scholar
  • 50 Nery PB, Beanlands RS, Nair GM. , et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014; 25 (08) 875-881
    CrossrefPubMedGoogle Scholar
  • 51 Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol 2005; 96 (02) 276-282
    CrossrefPubMedGoogle Scholar
  • 52 Thachil A, Christopher J, Sastry BK. , et al. Monomorphic ventricular tachycardia and mediastinal adenopathy due to granulomatous infiltration in patients with preserved ventricular function. J Am Coll Cardiol 2011; 58 (01) 48-55
    CrossrefPubMedGoogle Scholar
  • 53 Schuller JL, Olson MD, Zipse MM. , et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol 2011; 22 (11) 1243-1248
    CrossrefPubMedGoogle Scholar
  • 54 Mehta D, Willner JM, Akhrass PR. Atrial fibrillation in cardiac sarcoidosis. J Atr Fibrillation 2015; 8 (04) 1288
    PubMedGoogle Scholar
  • 55 Viles-Gonzalez JF, Pastori L, Fischer A, Wisnivesky JP, Goldman MG, Mehta D. Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. Chest 2013; 143 (04) 1085-1090
    CrossrefPubMedGoogle Scholar
  • 56 Zipse MM, Sauer WH. Electrophysiologic manifestations of cardiac sarcoidosis. Curr Opin Pulm Med 2013; 19 (05) 485-492
    CrossrefPubMedGoogle Scholar
  • 57 Yazaki Y, Hongo M, Hiroyoshi Y. , et al. Cardiac sarcoidosis in Japan: treatment and prognosis. In: Sekiguchi M, Richardson PJ. , eds. Prognosis and Treatment of Cardiomyopathy and Myocarditis. Tokyo, Japan: University of Tokyo Press; 1994: 341-353
    Google Scholar
  • 58 Moore SA, Abbara S, Mak GS, Mark EJ, Stone JR. Case records of the Massachusetts General Hospital. Case 22-2016. A 65-year-old man with syncope, dyspnea, and leg edema. N Engl J Med 2016; 375 (03) 262-272
    CrossrefPubMedGoogle Scholar
  • 59 Zoneraich S, Gupta MP, Mehta J, Zoneraich O, Wessely Z. Myocardial sarcoidosis presenting as acute mitral insufficiency. Chest 1974; 66 (04) 452-454
    CrossrefPubMedGoogle Scholar
  • 60 Desai MY, Fallert MA. Rapidly progressing congestive heart failure due to cardiac sarcoidosis involving papillary muscles: a case report and brief review of the literature. Cardiol Rev 2003; 11 (04) 163-168
    CrossrefPubMedGoogle Scholar
  • 61 Raftery EB, Oakley CM, Goodwin JF. Acute subvalvar mitral incompetence. Lancet 1966; 2 (7459): 360-365
    PubMedGoogle Scholar
  • 62 Israel RH, Poe RH. Massive pericardial effusion in sarcoidosis. Respiration 1994; 61 (03) 176-180
    CrossrefPubMedGoogle Scholar
  • 63 Garrett J, O'Neill H, Blake S. Constrictive pericarditis associated with sarcoidosis. Am Heart J 1984; 107 (02) 394
    PubMedGoogle Scholar
  • 64 Shiff AD, Blatt CJ, Colp C. Recurrent pericardial effusion secondary to sarcoidosis of the pericardium. N Engl J Med 1969; 281 (03) 141-143
    CrossrefPubMedGoogle Scholar
  • 65 Kinney E, Murthy R, Ascunce G, Donohoe R, Zelis R. Pericardial effusions in sarcoidosis. Chest 1979; 76 (04) 476-478
    CrossrefPubMedGoogle Scholar
  • 66 Gregor P, Widimsky P, Sladkova T, Petrikova J, Cervenka V, Visek V. Echocardiography in sarcoidosis. Jpn Heart J 1984; 25 (04) 499-508
    CrossrefPubMedGoogle Scholar
  • 67 Verkleeren JL, Glover MU, Bloor C, Joswig BC. Cardiac tamponade secondary to sarcoidosis. Am Heart J 1983; 106 (03) 601-603
    CrossrefPubMedGoogle Scholar
  • 68 Angomachalelis N, Hourzamanis A, Salem N. , et al. Pericardial effusion concomitant with specific heart muscle disease in systemic sarcoidosis. Postgrad Med J 1994; 70 (Suppl. 01) S8-S12
    PubMedGoogle Scholar
  • 69 Barton JH, Tavora F, Farb A, Li L, Burke AP. Unusual cardiovascular manifestations of sarcoidosis, a report of three cases: coronary artery aneurysm with myocardial infarction, symptomatic mitral valvular disease, and sudden death from ruptured splenic artery. Cardiovasc Pathol 2010; 19 (04) e119-e123
    CrossrefPubMedGoogle Scholar
  • 70 Wait JL, Movahed A. Anginal chest pain in sarcoidosis. Thorax 1989; 44 (05) 391-395
    CrossrefPubMedGoogle Scholar
  • 71 Lam CS, Tolep KA, Metke MP, Glockner J, Cooper Jr LT. Coronary sarcoidosis presenting as acute coronary syndrome. Clin Cardiol 2009; 32 (06) E68-E71
    PubMedGoogle Scholar
  • 72 Ward EV, Nazari J, Edelman RR. Coronary artery vasculitis as a presentation of cardiac sarcoidosis. Circulation 2012; 125 (06) e344-e346
    CrossrefPubMedGoogle Scholar
  • 73 Ryu SJ, Hong YK, Shin S, Cho S, Yoon SJ. Spontaneous regression of cardiac sarcoidosis resulting in total occlusion of coronary artery and ventricular aneurysm. Korean J Intern Med 2017
    PubMedGoogle Scholar
  • 74 Jain A, Starek PJ, Delany DL. Ventricular tachycardia and ventricular aneurysm due to unrecognized sarcoidosis. Clin Cardiol 1990; 13 (10) 738-740
    CrossrefPubMedGoogle Scholar
  • 75 Kosuge H, Noda M, Kakuta T, Kishi Y, Isobe M, Numano F. Left ventricular apical aneurysm in cardiac sarcoidosis. Jpn Heart J 2001; 42 (02) 265-269
    CrossrefPubMedGoogle Scholar
  • 76 Marks A, Anderson MH, Harrison NK. Ventricular aneurysm secondary to sarcoid disease. Heart 2004; 90 (06) 694
    CrossrefPubMedGoogle Scholar
  • 77 Lull RJ, Dunn BE, Gregoratos G, Cox WA, Fisher GW. Ventricular aneurysm due to cardiac sarcoidosis with surgical cure of refractory ventricular tachycardia. Am J Cardiol 1972; 30 (03) 282-287
    CrossrefPubMedGoogle Scholar
  • 78 Haraki T, Ueda K, Shintani H, Hayashi T, Taki J, Mabuchi H. Spontaneous development of left ventricular aneurysm in a patient with untreated cardiac sarcoidosis. Circ J 2002; 66 (05) 519-521
    CrossrefPubMedGoogle Scholar
  • 79 Pedrotti P, Ammirati E, Bonacina E, Roghi A. Ventricular aneurysms in cardiac sarcoidosis: from physiopathology to surgical treatment through a clinical case presenting with ventricular arrhythmias. Int J Cardiol 2015; 186: 294-296
    CrossrefPubMedGoogle Scholar
  • 80 Isobe M, Tezuka D. Isolated cardiac sarcoidosis: clinical characteristics, diagnosis and treatment. Int J Cardiol 2015; 182: 132-140
    CrossrefPubMedGoogle Scholar
  • 81 Roberts WC, Chung MS, Ko JM, Capehart JE, Hall SA. Morphologic features of cardiac sarcoidosis in native hearts of patients having cardiac transplantation. Am J Cardiol 2014; 113 (04) 706-712
    CrossrefPubMedGoogle Scholar
  • 82 Kandolin R, Lehtonen J, Graner M. , et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011; 270 (05) 461-468
    CrossrefPubMedGoogle Scholar
  • 83 Hiraga H, Iwai K, Hiroe M, Omori F, Sekiguchi M, Tachibana T. Guidelines for Diagnosis of Cardiac Sarcoidosis: Study Report on Diffuse Pulmonary Diseases. Tokyo: The Japanese Ministry of Health and Ministry; 1993: 23-24
    Google Scholar
  • 84 Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager Jr H. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (01) 75-86
    PubMedGoogle Scholar
  • 85 Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995; 107 (02) 330-334
    CrossrefPubMedGoogle Scholar
  • 86 White JA, Rajchl M, Butler J, Thompson RT, Prato FS, Wisenberg G. Active cardiac sarcoidosis: first clinical experience of simultaneous positron emission tomography--magnetic resonance imaging for the diagnosis of cardiac disease. Circulation 2013; 127 (22) e639-e641
    CrossrefPubMedGoogle Scholar
  • 87 Patel MR, Cawley PJ, Heitner JF. , et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120 (20) 1969-1977
    CrossrefPubMedGoogle Scholar
  • 88 Yang Y, Safka K, Graham JJ. , et al. Correlation of late gadolinium enhancement MRI and quantitative T2 measurement in cardiac sarcoidosis. J Magn Reson Imaging 2014; 39 (03) 609-616
    CrossrefPubMedGoogle Scholar
  • 89 Youssef G, Leung E, Mylonas I. , et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53 (02) 241-248
    CrossrefPubMedGoogle Scholar
  • 90 Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010; 52 (04) 336-346
    CrossrefPubMedGoogle Scholar
  • 91 Akbar JJ, Meyer CA, Shipley RT, Vagal AS. Cardiopulmonary imaging in sarcoidosis. Clin Chest Med 2008; 29 (03) 429-443 , viii
    CrossrefPubMedGoogle Scholar
  • 92 Thunéll M, Bjerle P, Stjernberg N. ECG abnormalities in patients with sarcoidosis. Acta Med Scand 1983; 213 (02) 115-118
    PubMedGoogle Scholar
  • 93 Gibbons WJ, Levy RD, Nava S. , et al. Subclinical cardiac dysfunction in sarcoidosis. Chest 1991; 100 (01) 44-50
    CrossrefPubMedGoogle Scholar
  • 94 Schuller JL, Lowery CM, Zipse M. , et al. Diagnostic utility of signal-averaged electrocardiography for detection of cardiac sarcoidosis. Ann Noninvasive Electrocardiol 2011; 16 (01) 70-76
    CrossrefPubMedGoogle Scholar
  • 95 Suzuki T, Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest 1994; 106 (04) 1021-1024
    CrossrefPubMedGoogle Scholar
  • 96 Thunell M, Bjerle P, Karp K, Stjernberg N. Exercise test in patients with sarcoidosis. The importance of repolarization disturbances. Acta Med Scand 1988; 223 (01) 69-73
    PubMedGoogle Scholar
  • 97 Lewin RF, Mor R, Spitzer S, Arditti A, Hellman C, Agmon J. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J 1985; 110 (1 Pt 1): 116-122
    CrossrefPubMedGoogle Scholar
  • 98 Moiseyev SV, Kornev BM, Shatkovsky NP, Eventov AZ, Pisareva NA. Non-invasive diagnosis of cardiac sarcoidosis. Lancet 1987; 2 (8561): 739-740
    PubMedGoogle Scholar
  • 99 Winters SL, Cohen M, Greenberg S. , et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 1991; 18 (04) 937-943
    CrossrefPubMedGoogle Scholar
  • 100 Padilla ML. Cardiac sarcoidosis. In: Baughman RP. , ed. Sarcoidosis. New York, NY: Informa USA Inc.; 2010: 515-551
    Google Scholar
  • 101 Angomachalelis N, Hourzamanis A, Vamvalis C, Gavrielides A. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic sarcoidosis. Postgrad Med J 1992; 68 (Suppl. 01) S52-S56
    PubMedGoogle Scholar
  • 102 Mañá J. Nuclear imaging. 67Gallium, 201thallium, 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography. Clin Chest Med 1997; 18 (04) 799-811
    CrossrefPubMedGoogle Scholar
  • 103 Hirose Y, Ishida Y, Hayashida K. , et al. Myocardial involvement in patients with sarcoidosis. An analysis of 75 patients. Clin Nucl Med 1994; 19 (06) 522-526
    CrossrefPubMedGoogle Scholar
  • 104 Tawarahara K, Kurata C, Okayama K, Kobayashi A, Yamazaki N. Thallium-201 and gallium 67 single photon emission computed tomographic imaging in cardiac sarcoidosis. Am Heart J 1992; 124 (05) 1383-1384
    CrossrefPubMedGoogle Scholar
  • 105 Taki J, Nakajima K, Bunko H, Ohguchi M, Tonami N, Hisada K. Cardiac sarcoidosis demonstrated by Tl-201 and Ga-67 SPECT imaging. Clin Nucl Med 1990; 15 (09) 636-639
    CrossrefPubMedGoogle Scholar
  • 106 Le Guludec D, Menad F, Faraggi M, Weinmann P, Battesti JP, Valeyre D. Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy. Chest 1994; 106 (06) 1675-1682
    CrossrefPubMedGoogle Scholar
  • 107 Tellier P, Valeyre D, Nitenberg A, Foult JM, Bedig G, Battesti JP. Cardiac sarcoidosis: reversion of myocardial perfusion abnormalities by dipyridamole. Eur J Nucl Med 1985; 11 (6-7): 201-204
    PubMedGoogle Scholar
  • 108 Yamamoto N, Gotoh K, Yagi Y. , et al. Thallium-201 myocardial SPECT findings at rest in sarcoidosis. Ann Nucl Med 1993; 7 (02) 97-103
    CrossrefPubMedGoogle Scholar
  • 109 Kurata C, Sakata K, Taguchi T. , et al. SPECT imaging with Tl-201 and Ga-67 in myocardial sarcoidosis. Clin Nucl Med 1990; 15 (06) 408-411
    CrossrefPubMedGoogle Scholar
  • 110 Tajima T, Naito T, Dohi Y, Miyamae T. Ga-67 and Tl-201 imaging in sarcoidosis involving the myocardium. Clin Nucl Med 1981; 6 (03) 120-121
    CrossrefPubMedGoogle Scholar
  • 111 Nagatomo Y, Imamura T, Koiwaya Y. , et al. Thallium-201 and gallium-67 myocardial scintigraphy for the evaluation of sarcoid involvement. Clin Nucl Med 1987; 12 (04) 335-336
    CrossrefPubMedGoogle Scholar
  • 112 Forman MB, Sandler MP, Sacks GA, Kronenberg MW, Powers TA. Radionuclide imaging in myocardial sarcoidosis. Demonstration of myocardial uptake of technetium pyrophosphate99m and gallium. Chest 1983; 83 (03) 578-580
    CrossrefPubMedGoogle Scholar
  • 113 Eguchi M, Tsuchihashi K, Hotta D. , et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology 2000; 94 (03) 193-199
    CrossrefPubMedGoogle Scholar
  • 114 Kaminaga T, Takeshita T, Yamauchi T, Kawamura H, Yasuda M. The role of iodine-123-labeled 15-(p-iodophenyl)-3R,S-methylpentadecanoic acid scintigraphy in the detection of local myocardial involvement of sarcoidosis. Int J Cardiol 2004; 94 (01) 99-103
    CrossrefPubMedGoogle Scholar
  • 115 Matsuo S, Nakamura Y, Matsui T, Matsumoto T, Kinoshita M. Detection of denervated but viable myocardium in cardiac sarcoidosis with I-123 MIBG and Tl-201 SPECT imaging. Ann Nucl Med 2001; 15 (04) 373-375
    CrossrefPubMedGoogle Scholar
  • 116 Knapp WH, Bentrup A, Ohlmeier H. Indium-111-labelled antimyosin antibody imaging in a patient with cardiac sarcoidosis. Eur J Nucl Med 1993; 20 (01) 80-82
    CrossrefPubMedGoogle Scholar
  • 117 Komada T, Suzuki K, Ishiguchi H. , et al. Magnetic resonance imaging of cardiac sarcoidosis: an evaluation of the cardiac segments and layers that exhibit late gadolinium enhancement. Nagoya J Med Sci 2016; 78 (04) 437-446
    PubMedGoogle Scholar
  • 118 Aggarwal NR, Snipelisky D, Young PM, Gersh BJ, Cooper LT, Chareonthaitawee P. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 2015; 16 (09) 949-958
    PubMedGoogle Scholar
  • 119 Kadkhodayan A, Chareonthaitawee P, Raman SV, Cooper LT. Imaging of inflammation in unexplained cardiomyopathy. JACC Cardiovasc Imaging 2016; 9 (05) 603-617
    CrossrefPubMedGoogle Scholar
  • 120 Tahara N, Tahara A, Nitta Y. , et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010; 3 (12) 1219-1228
    CrossrefPubMedGoogle Scholar
  • 121 Matthews R, Bench T, Meng H, Franceschi D, Relan N, Brown DL. Diagnosis and monitoring of cardiac sarcoidosis with delayed-enhanced MRI and 18F-FDG PET-CT. J Nucl Cardiol 2012; 19 (04) 807-810
    CrossrefPubMedGoogle Scholar
  • 122 Nishiyama Y, Yamamoto Y, Fukunaga K. , et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006; 47 (10) 1571-1576
    PubMedGoogle Scholar
  • 123 Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35 (08) 1537-1543
    CrossrefPubMedGoogle Scholar
  • 124 Blankstein R, Osborne M, Naya M. , et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63 (04) 329-336
    CrossrefPubMedGoogle Scholar
  • 125 Heymans S, Eriksson U, Lehtonen J, Cooper Jr LT. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol 2016; 68 (21) 2348-2364
    CrossrefPubMedGoogle Scholar
  • 126 Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132 (06) 1949-1953
    CrossrefPubMedGoogle Scholar
  • 127 Mostard RL, Verschakelen JA, van Kroonenburgh MJ. , et al. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med 2013; 107 (03) 439-447
    CrossrefPubMedGoogle Scholar
  • 128 Mostard RL, Vöö S, van Kroonenburgh MJ. , et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011; 105 (12) 1917-1924
    CrossrefPubMedGoogle Scholar
  • 129 Keijsers RG, Verzijlbergen EJ, van den Bosch JM. , et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (02) 123-129
    PubMedGoogle Scholar
  • 130 Sobic-Saranovic D, Artiko V, Obradovic V. FDG PET imaging in sarcoidosis. Semin Nucl Med 2013; 43 (06) 404-411
    CrossrefPubMedGoogle Scholar
  • 131 Okumura W, Iwasaki T, Toyama T. , et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45 (12) 1989-1998
    PubMedGoogle Scholar
  • 132 Okumura W, Iwasaki T, Ueda T. , et al. [Usefulness of 18F-FDG PET for diagnosis of cardiac sarcoidosis]. Kaku Igaku 1999; 36 (04) 341-348
    PubMedGoogle Scholar
  • 133 Yamagishi H, Shirai N, Takagi M. , et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 2003; 44 (07) 1030-1036
    PubMedGoogle Scholar
  • 134 Simonen P, Lehtonen J, Kandolin R. , et al. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol 2015; 116 (10) 1581-1585
    CrossrefPubMedGoogle Scholar
  • 135 Ishimaru S, Tsujino I, Takei T. , et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005; 26 (15) 1538-1543
    CrossrefPubMedGoogle Scholar
  • 136 Shelke AB, Aurangabadkar HU, Bradfield JS, Ali Z, Kumar KS, Narasimhan C. Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis. Int J Cardiol 2017; 228: 717-722
    CrossrefPubMedGoogle Scholar
  • 137 Takeda N, Yokoyama I, Hiroi Y. , et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 2002; 105 (09) 1144-1145
    CrossrefPubMedGoogle Scholar
  • 138 Lu Y, Grant C, Xie K, Sweiss NJ. Suppression of myocardial 18F-FDG uptake through prolonged high-fat, high-protein, and very-low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. Clin Nucl Med 2017; 42 (02) 88-94
    CrossrefPubMedGoogle Scholar
  • 139 Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med 2014; 55 (01) 99-106
    CrossrefPubMedGoogle Scholar
  • 140 Ohira H, Tsujino I, Ishimaru S. , et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35 (05) 933-941
    CrossrefPubMedGoogle Scholar
  • 141 Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol 2005; 184 (01) 249-254
    CrossrefPubMedGoogle Scholar
  • 142 Giesbrandt KJ, Bolan CW, Shapiro BP, Edwards WD, Mergo PJ. Diffuse diseases of the myocardium: MRI-pathologic review of cardiomyopathies with dilatation. AJR Am J Roentgenol 2013; 200 (03) W274-82
    PubMedGoogle Scholar
  • 143 Ordovas KG, Higgins CB. Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology 2011; 261 (02) 358-374
    CrossrefPubMedGoogle Scholar
  • 144 Schulz-Menger J, Wassmuth R, Abdel-Aty H. , et al. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart 2006; 92 (03) 399-400
    PubMedGoogle Scholar
  • 145 Serra JJ, Monte GU, Mello ES. , et al. Images in cardiovascular medicine. Cardiac sarcoidosis evaluated by delayed-enhanced magnetic resonance imaging. Circulation 2003; 107 (20) e188-e189
    PubMedGoogle Scholar
  • 146 Ferreira VM, Piechnik SK. Seeing beyond the obvious: subclinical cardiac sarcoidosis revealed by cardiovascular magnetic resonance mapping. Circ Cardiovasc Imaging 2016; 9 (11) 9
    CrossrefPubMedGoogle Scholar
  • 147 Matoh F, Satoh H, Shiraki K. , et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J Cardiol 2008; 51 (03) 179-188
    CrossrefPubMedGoogle Scholar
  • 148 Watanabe E, Kimura F, Nakajima T. , et al. Late gadolinium enhancement in cardiac sarcoidosis: characteristic magnetic resonance findings and relationship with left ventricular function. J Thorac Imaging 2013; 28 (01) 60-66
    CrossrefPubMedGoogle Scholar
  • 149 Chandra M, Silverman ME, Oshinski J, Pettigrew R. Diagnosis of cardiac sarcoidosis aided by MRI. Chest 1996; 110 (02) 562-565
    CrossrefPubMedGoogle Scholar
  • 150 Shimada T, Shimada K, Sakane T. , et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001; 110 (07) 520-527
    CrossrefPubMedGoogle Scholar
  • 151 Doherty MJ, Kumar SK, Nicholson AA, McGivern DV. Cardiac sarcoidosis: the value of magnetic resonance imaging in diagnosis and assessment of response to treatment. Respir Med 1998; 92 (04) 697-699
    CrossrefPubMedGoogle Scholar
  • 152 Eliasch H, Juhlin-Dannfelt A, Sjögren I, Terent A. Magnetic resonance imaging as an aid to the diagnosis and treatment evaluation of suspected myocardial sarcoidosis in a fighter pilot. Aviat Space Environ Med 1995; 66 (10) 1010-1013
    PubMedGoogle Scholar
  • 153 Matsuki M, Matsuo M. MR findings of myocardial sarcoidosis. Clin Radiol 2000; 55 (04) 323-325
    CrossrefPubMedGoogle Scholar
  • 154 Bajaj AK, Kopelman HA, Echt DS. Cardiac sarcoidosis with sudden death: treatment with the automatic implantable cardioverter defibrillator. Am Heart J 1988; 116 (2 Pt 1): 557-560
    CrossrefPubMedGoogle Scholar
  • 155 Danias PG. Gadolinium-enhanced cardiac magnetic resonance imaging: expanding the spectrum of clinical applications. Am J Med 2001; 110 (07) 591-592
    CrossrefPubMedGoogle Scholar
  • 156 Vignaux O, Dhote R, Duboc D. , et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 2002; 122 (06) 1895-1901
    CrossrefPubMedGoogle Scholar
  • 157 Smedema JP, Snoep G, van Kroonenburgh MP. , et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45 (10) 1683-1690
    CrossrefPubMedGoogle Scholar
  • 158 Ichinose A, Otani H, Oikawa M. , et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR Am J Roentgenol 2008; 191 (03) 862-869
    CrossrefPubMedGoogle Scholar
  • 159 Cheong BY, Muthupillai R, Nemeth M. , et al. The utility of delayed-enhancement magnetic resonance imaging for identifying nonischemic myocardial fibrosis in asymptomatic patients with biopsy-proven systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (01) 39-46
    PubMedGoogle Scholar
  • 160 Ishibashi K, Takeda M, Yamahara Y. Clinical utility of a magnetic resonance-conditional pacemaker in a patient with cardiac sarcoidosis. Intern Med 2013; 52 (12) 1341-1345
    CrossrefPubMedGoogle Scholar
  • 161 Yoshida A, Ishibashi-Ueda H, Yamada N. , et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail 2013; 15 (02) 166-175
    CrossrefPubMedGoogle Scholar
  • 162 Shafee MA, Fukuda K, Wakayama Y. , et al. Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. J Cardiol 2012; 60 (06) 448-453
    CrossrefPubMedGoogle Scholar
  • 163 Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 2014; 146 (04) 1064-1072
    CrossrefPubMedGoogle Scholar
  • 164 Ekström K, Lehtonen J, Hänninen H, Kandolin R, Kivistö S, Kupari M. Magnetic resonance imaging as a predictor of survival free of life-threatening arrhythmias and transplantation in cardiac sarcoidosis. J Am Heart Assoc 2016; 5 (05) 5
    PubMedGoogle Scholar
  • 165 Greulich S, Kitterer D, Latus J. , et al. Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction. Circ Cardiovasc Imaging 2016; 9 (11) 9
    CrossrefPubMedGoogle Scholar
  • 166 Kono T, Ogimoto A, Saito M. , et al. Cardiac magnetic resonance imaging for assessment of steroid therapy in a patient with cardiac sarcoidosis and a magnetic resonance-conditional pacemaker. Int J Cardiol 2014; 176 (03) e89-e91
    CrossrefPubMedGoogle Scholar
  • 167 Takaya Y, Kusano KF, Nakamura K. , et al. Reduction of myocardial inflammation with steroid is not necessarily associated with improvement in left ventricular function in patients with cardiac sarcoidosis: predictors of functional improvement. Int J Cardiol 2014; 176 (02) 522-525
    CrossrefPubMedGoogle Scholar
  • 168 Wilkoff BL, Bello D, Taborsky M. , et al; EnRhythm MRI SureScan Pacing System Study Investigators. Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment. Heart Rhythm 2011; 8 (01) 65-73
    CrossrefPubMedGoogle Scholar
  • 169 Stevens SM, Tung R, Rashid S. , et al. Device artifact reduction for magnetic resonance imaging of patients with implantable cardioverter-defibrillators and ventricular tachycardia: late gadolinium enhancement correlation with electroanatomic mapping. Heart Rhythm 2014; 11 (02) 289-298
    CrossrefPubMedGoogle Scholar
  • 170 Ishikawa T, Kondoh H, Nakagawa S, Koiwaya Y, Tanaka K. Steroid therapy in cardiac sarcoidosis. Increased left ventricular contractility concomitant with electrocardiographic improvement after prednisolone. Chest 1984; 85 (03) 445-447
    CrossrefPubMedGoogle Scholar
  • 171 Lorell B, Alderman EL, Mason JW. Cardiac sarcoidosis. Diagnosis with endomyocardial biopsy and treatment with corticosteroids. Am J Cardiol 1978; 42 (01) 143-146
    CrossrefPubMedGoogle Scholar
  • 172 Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999; 138 (2 Pt 1): 299-302
    CrossrefPubMedGoogle Scholar
  • 173 Ratner SJ, Fenoglio Jr JJ, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest 1986; 90 (04) 528-533
    CrossrefPubMedGoogle Scholar
  • 174 Shields RC, Tazelaar HD, Berry GJ, Cooper Jr LT. The role of right ventricular endomyocardial biopsy for idiopathic giant cell myocarditis. J Card Fail 2002; 8 (02) 74-78
    CrossrefPubMedGoogle Scholar
  • 175 Cooper LT, Baughman KL, Feldman AM. , et al; American Heart Association; American College of Cardiology; European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007; 116 (19) 2216-2233
    CrossrefPubMedGoogle Scholar
  • 176 Felker GM, Hu W, Hare JM, Hruban RH, Baughman KL, Kasper EK. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltimore) 1999; 78 (04) 270-283
    Google Scholar
  • 177 Veinot JP. Diagnostic endomyocardial biopsy pathology: secondary myocardial diseases and other clinical indications - a review. Can J Cardiol 2002; 18 (03) 287-296
    PubMedGoogle Scholar
  • 178 Liang JJ, Hebl VB, DeSimone CV. , et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail 2014; 2 (05) 466-473
    CrossrefPubMedGoogle Scholar
  • 179 Honda Y, Nagai T, Ikeda Y. , et al. Myocardial immunocompetent cells and macrophage phenotypes as histopathological surrogates for diagnosis of cardiac sarcoidosis in Japanese. J Am Heart Assoc 2016; 5 (11) 5
    PubMedGoogle Scholar
  • 180 Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis?. Circulation 1996; 94 (05) 983-991
    CrossrefPubMedGoogle Scholar
  • 181 Dechering DG, Kochhäuser S, Wasmer K. , et al. Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2013; 10 (02) 158-164
    CrossrefPubMedGoogle Scholar
  • 182 Choo WK, Denison AR, Miller DR, Dempsey OJ, Dawson DK, Broadhurst PA. Cardiac sarcoid or arrhythmogenic right ventricular cardiomyopathy: a role for positron emission tomography (PET)?. J Nucl Cardiol 2013; 20 (03) 479-480
    CrossrefPubMedGoogle Scholar
  • 183 Litovsky SH, Burke AP, Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 1996; 9 (12) 1126-1134
    PubMedGoogle Scholar
  • 184 Okura Y, Dec GW, Hare JM. , et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 2003; 41 (02) 322-329
    PubMedGoogle Scholar
  • 185 Cooper Jr LT, Hare JM, Tazelaar HD. , et al; Giant Cell Myocarditis Treatment Trial Investigators. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102 (11) 1535-1539
    CrossrefPubMedGoogle Scholar
  • 186 Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss HP, Cooper LT. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol 2015; 115 (12) 1733-1738
    CrossrefPubMedGoogle Scholar
  • 187 Yoshizawa S, Kato TS, Mancini D, Marboe CC. Outcome of patients having heart transplantation for lymphocytic myocarditis. Am J Cardiol 2013; 112 (03) 405-410
    CrossrefPubMedGoogle Scholar
  • 188 Mavrogeni S, Sfikakis PP, Gialafos E. , et al. Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases. Arthritis Care Res (Hoboken) 2014; 66 (01) 104-112
    CrossrefPubMedGoogle Scholar
  • 189 Kang EJ, Kim SM, Choe YH, Lee GY, Lee KN, Kim DK. Takayasu arteritis: assessment of coronary arterial abnormalities with 128-section dual-source CT angiography of the coronary arteries and aorta. Radiology 2014; 270 (01) 74-81
    CrossrefPubMedGoogle Scholar
  • 190 Miszalski-Jamka T, Szczeklik W, Sokołowska B. , et al. Standard and feature tracking magnetic resonance evidence of myocardial involvement in Churg-Strauss syndrome and granulomatosis with polyangiitis (Wegener's) in patients with normal electrocardiograms and transthoracic echocardiography. Int J Cardiovasc Imaging 2013; 29 (04) 843-853
    CrossrefPubMedGoogle Scholar
  • 191 Mohty D, Damy T, Cosnay P. , et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 2013; 106 (10) 528-540
    CrossrefPubMedGoogle Scholar
  • 192 Marques N, Gan VC, Leo YS. Dengue myocarditis in Singapore: two case reports. Infection 2013; 41 (03) 709-714
    CrossrefPubMedGoogle Scholar
  • 193 Nunes MC, Dones W, Morillo CA, Encina JJ, Ribeiro AL. ; Council on Chagas Disease of the Interamerican Society of Cardiology. Chagas disease: an overview of clinical and epidemiological aspects. J Am Coll Cardiol 2013; 62 (09) 767-776
    CrossrefPubMedGoogle Scholar
  • 194 Bonney KM, Engman DM. Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead. Am J Pathol 2015; 185 (06) 1537-1547
    CrossrefPubMedGoogle Scholar
  • 195 Kühl U, Pauschinger M, Noutsias M. , et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 2005; 111 (07) 887-893
    CrossrefPubMedGoogle Scholar
  • 196 Homsi M, Alsayed L, Safadi B, Mahenthiran J, Das MK. Fragmented QRS complexes on 12-lead ECG: a marker of cardiac sarcoidosis as detected by gadolinium cardiac magnetic resonance imaging. Ann Noninvasive Electrocardiol 2009; 14 (04) 319-326
    CrossrefPubMedGoogle Scholar
  • 197 Takagi M, Yokoyama Y, Aonuma K, Aihara N, Hiraoka M. ; Japan Idiopathic Ventricular Fibrillation Study (J-IVFS) Investigators. Clinical characteristics and risk stratification in symptomatic and asymptomatic patients with brugada syndrome: multicenter study in Japan. J Cardiovasc Electrophysiol 2007; 18 (12) 1244-1251
    CrossrefPubMedGoogle Scholar
  • 198 Priori SG, Gasparini M, Napolitano C. , et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012; 59 (01) 37-45
    CrossrefPubMedGoogle Scholar
  • 199 Catalano O, Antonaci S, Moro G. , et al. Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. Eur Heart J 2009; 30 (18) 2241-2248
    CrossrefPubMedGoogle Scholar
  • 200 Quarta G, Husain SI, Flett AS. , et al. Arrhythmogenic right ventricular cardiomyopathy mimics: role of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2013; 15: 16
    CrossrefPubMedGoogle Scholar
  • 201 Steckman DA, Schneider PM, Schuller JL. , et al. Utility of cardiac magnetic resonance imaging to differentiate cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2012; 110 (04) 575-579
    CrossrefPubMedGoogle Scholar
  • 202 Mehta D, Lubitz SA, Frankel Z. , et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133 (06) 1426-1435
    CrossrefPubMedGoogle Scholar
  • 203 Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2011; 4 (01) 43-48
    CrossrefPubMedGoogle Scholar
  • 204 Uusimaa P, Ylitalo K, Anttonen O. , et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace 2008; 10 (06) 760-766
    CrossrefPubMedGoogle Scholar
  • 205 Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20 (02) 133-137
    PubMedGoogle Scholar
  • 206 Nagai T, Nagano N, Sugano Y. , et al. Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis. Am J Cardiol 2016; 117 (06) 966-971
    CrossrefPubMedGoogle Scholar
  • 207 Miyazaki S, Funabashi N, Nagai T. , et al. Cardiac sarcoidosis complicated with atrioventricular block and wall thinning, edema and fibrosis in left ventricle: confirmed recovery to normal sinus rhythm and visualization of edema improvement by administration of predonisolone. Int J Cardiol 2011; 150 (01) e4-e10
    CrossrefPubMedGoogle Scholar
  • 208 Pierre-Louis B, Prasad A, Frishman WH. Cardiac manifestations of sarcoidosis and therapeutic options. Cardiol Rev 2009; 17 (04) 153-158
    CrossrefPubMedGoogle Scholar
  • 209 Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol 2013; 29 (09) 1034-1041
    CrossrefPubMedGoogle Scholar
  • 210 Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28 (03) 627-636
    CrossrefPubMedGoogle Scholar
  • 211 Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183 (05) 573-581
    CrossrefPubMedGoogle Scholar
  • 212 Sugisaki K, Yamaguchi T, Nagai S. , et al. Clinical characteristics of 195 Japanese sarcoidosis patients treated with oral corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20 (03) 222-226
    PubMedGoogle Scholar
  • 213 Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol 2011; 16 (02) 140-147
    CrossrefPubMedGoogle Scholar
  • 214 Yodogawa K, Seino Y, Shiomura R. , et al. Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J Cardiol 2013; 62 (05) 320-325
    CrossrefPubMedGoogle Scholar
  • 215 Nagai T, Nagano N, Sugano Y. , et al. Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis. Circ J 2015; 79 (07) 1593-1600
    CrossrefPubMedGoogle Scholar
  • 216 Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med 2010; 31 (04) 501-518
    Article in Thieme ConnectPubMedGoogle Scholar
  • 217 Wang T, Weigt SS, Belperio JA, Lynch III JP. Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring. Semin Respir Crit Care Med 2011; 32 (03) 346-370
    Article in Thieme ConnectPubMedGoogle Scholar
  • 218 Lynch III JP, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155 (02) 395-420
    CrossrefPubMedGoogle Scholar
  • 219 Baughman RP, Lower EE. Medical therapy of sarcoidosis. Semin Respir Crit Care Med 2014; 35 (03) 391-406
    Article in Thieme ConnectPubMedGoogle Scholar
  • 220 Demeter SL. Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest 1988; 94 (01) 202-203
    CrossrefPubMedGoogle Scholar
  • 221 Barnabe C, McMeekin J, Howarth A, Martin L. Successful treatment of cardiac sarcoidosis with infliximab. J Rheumatol 2008; 35 (08) 1686-1687
    PubMedGoogle Scholar
  • 222 Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol 2007; 26 (11) 2001-2003
    CrossrefPubMedGoogle Scholar
  • 223 Stees CS, Khoo MS, Lowery CM, Sauer WH. Ventricular tachycardia storm successfully treated with immunosuppression and catheter ablation in a patient with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2011; 22 (02) 210-213
    PubMedGoogle Scholar
  • 224 Okabe T, Yakushiji T, Hiroe M. , et al. Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction. ESC Heart Fail 2016; 3 (04) 288-292
    PubMedGoogle Scholar
  • 225 Crouser ED, Lozanski G, Fox CC, Hauswirth DW, Raveendran R, Julian MW. The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-alpha therapy. Chest 2010; 137 (06) 1432-1435
    CrossrefPubMedGoogle Scholar
  • 226 Beccastrini E, Vannozzi L, Bacherini D, Squatrito D, Emmi L. Successful treatment of ocular sarcoidosis with rituximab. Ocul Immunol Inflamm 2013; 21 (03) 244-246
    CrossrefPubMedGoogle Scholar
  • 227 Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 2012; 6: 1613-1618
    PubMedGoogle Scholar
  • 228 Belkhou A, Younsi R, El Bouchti I, El Hassani S. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine 2008; 75 (04) 511-512
    CrossrefPubMedGoogle Scholar
  • 229 Krause ML, Cooper LT, Chareonthaitawee P, Amin S. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford) 2016; 55 (01) 189-191
    CrossrefPubMedGoogle Scholar
  • 230 Mezaki T, Chinushi M, Washizuka T. , et al. Discrepancy between inducibility of ventricular tachycardia and activity of cardiac sarcoidosis. Requirement of defibrillator implantation for the inactive stage of cardiac sarcoidosis. Intern Med 2001; 40 (08) 731-735
    CrossrefPubMedGoogle Scholar
  • 231 Huang PL, Brooks R, Carpenter C, Garan H. Antiarrhythmic therapy guided by programmed electrical stimulation in cardiac sarcoidosis with ventricular tachycardia. Am Heart J 1991; 121 (2 Pt 1): 599-601
    CrossrefPubMedGoogle Scholar
  • 232 Kowey PR, Waxman HL, Greenspon A. , et al; Philadelphia Arrhythmia Group. Value of electrophysiologic testing in patients with previous myocardial infarction and nonsustained ventricular tachycardia. Am J Cardiol 1990; 65 (09) 594-598
    CrossrefPubMedGoogle Scholar
  • 233 Poll DS, Marchlinski FE, Buxton AE, Josephson ME. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. Am J Cardiol 1986; 58 (10) 992-997
    CrossrefPubMedGoogle Scholar
  • 234 Schuller JL, Zipse M, Crawford T. , et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012; 23 (09) 925-929
    CrossrefPubMedGoogle Scholar
  • 235 Shabetai R. Sarcoidosis and the heart. Curr Treat Options Cardiovasc Med 2000; 2 (05) 385-398
    CrossrefPubMedGoogle Scholar
  • 236 Stein E, Jackler I, Stimmel B, Stein W, Siltzbach LE. Asymptomatic electrocardiographic alterations in sarcoidosis. Am Heart J 1973; 86 (04) 474-477
    CrossrefPubMedGoogle Scholar
  • 237 Takada K, Ina Y, Yamamoto M, Satoh T, Morishita M. Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan. Clinical evaluation of corticosteroid therapy. Sarcoidosis 1994; 11 (02) 113-117
    PubMedGoogle Scholar
  • 238 Paz HL, McCormick DJ, Kutalek SP, Patchefsky A. The automated implantable cardiac defibrillator. Prophylaxis in cardiac sarcoidosis. Chest 1994; 106 (05) 1603-1607
    CrossrefPubMedGoogle Scholar
  • 239 Betensky BP, Tschabrunn CM, Zado ES. , et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012; 9 (06) 884-891
    CrossrefPubMedGoogle Scholar
  • 240 Chinushi M, Mezaki T, Aoki Y, Nakagawa I, Washizuka T, Aizawa Y. Demonstration of transient entrainment in monomorphic sustained ventricular tachycardia associated with cardiac sarcoidosis. Jpn Circ J 2000; 64 (08) 635-637
    CrossrefPubMedGoogle Scholar
  • 241 Andrié R, Gaertner FC, Skowasch D. Prevention of sudden cardiac death by the wearable cardioverter defibrillator in a young patient with cardiac sarcoidosis. Thorax 2017; 72 (03) 286-287
    CrossrefPubMedGoogle Scholar
  • 242 Epstein AE, DiMarco JP, Ellenbogen KA. , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51 (21) e1-e62
    CrossrefPubMedGoogle Scholar
  • 243 Kron J, Sauer W, Schuller J. , et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 2013; 15 (03) 347-354
    CrossrefPubMedGoogle Scholar
  • 244 Koplan BA, Soejima K, Baughman K, Epstein LM, Stevenson WG. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm 2006; 3 (08) 924-929
    CrossrefPubMedGoogle Scholar
  • 245 Hiramastu S, Tada H, Naito S, Oshima S, Taniguchi K. Steroid treatment deteriorated ventricular tachycardia in a patient with right ventricle-dominant cardiac sarcoidosis. Int J Cardiol 2009; 132 (02) e85-e87
    CrossrefPubMedGoogle Scholar
  • 246 Jefic D, Joel B, Good E. , et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 2009; 6 (02) 189-195
    CrossrefPubMedGoogle Scholar
  • 247 Muser D, Santangeli P, Pathak RK. , et al. Long-term outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2016; 9 (08) 9
    PubMedGoogle Scholar
  • 248 Harris IM, Guarino R. Cardiac sarcoidosis: a new approach to treatment. Cardiovasc Surg 1994; 2 (03) 420-422
    PubMedGoogle Scholar
  • 249 Chang TI, Chi NH, Chou NK. , et al. Isolated cardiac sarcoidosis in heart transplantation. Transplant Proc 2012; 44 (04) 903-906
    CrossrefPubMedGoogle Scholar
  • 250 Perkel D, Czer LS, Morrissey RP. , et al. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. Transplant Proc 2013; 45 (06) 2384-2386
    CrossrefPubMedGoogle Scholar
  • 251 Milman N, Andersen CB, Mortensen SA, Sander K. Cardiac sarcoidosis and heart transplantation: a report of four consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25 (01) 51-59
    PubMedGoogle Scholar
  • 252 Akashi H, Kato TS, Takayama H. , et al. Outcome of patients with cardiac sarcoidosis undergoing cardiac transplantation--single-center retrospective analysis. J Cardiol 2012; 60 (05) 407-410
    CrossrefPubMedGoogle Scholar
  • 253 Donsky AS, Escobar J, Capehart J, Roberts WC. Heart transplantation for undiagnosed cardiac sarcoidosis. Am J Cardiol 2002; 89 (12) 1447-1450
    CrossrefPubMedGoogle Scholar
  • 254 Theofilogiannakos EK, Pettit SJ, Ghazi A, Rassl D, Lewis C, Parameshwar J. Heart transplantation for advanced heart failure due to cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32 (03) 208-214
    PubMedGoogle Scholar
  • 255 Al-Kindi SG, Oliveira GH. Letter by Al-Kindi and Oliveira regarding article “cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study”. Circulation 2015; 132 (17) e211
    CrossrefPubMedGoogle Scholar
  • 256 Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant 2007; 26 (07) 714-717
    CrossrefPubMedGoogle Scholar
  • 257 Oni AA, Hershberger RE, Norman DJ. , et al. Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant 1992; 11 (2 Pt 1): 367-369
    PubMedGoogle Scholar
  • 258 Khan R, Tweedie EJ, Pflugfelder PW, White JA. Cardiac sarcoid in a heart transplant recipient: detection with cardiac magnetic resonance imaging. Transplant Proc 2010; 42 (05) 1976-1978
    CrossrefPubMedGoogle Scholar
  • 259 Luk A, Lee A, Ahn E, Soor GS, Ross HJ, Butany J. Cardiac sarcoidosis: recurrent disease in a heart transplant patient following pulmonary tuberculosis infection. Can J Cardiol 2010; 26 (07) e273-e275
    CrossrefPubMedGoogle Scholar
  • 260 Yager JE, Hernandez AF, Steenbergen C. , et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant 2005; 24 (11) 1988-1990
    CrossrefPubMedGoogle Scholar
  • 261 Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009; 16 (05) 801-810
    CrossrefPubMedGoogle Scholar
  • 262 Deng JC, Baughman RP, Lynch III JP. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med 2002; 23 (06) 513-527
    Article in Thieme ConnectPubMedGoogle Scholar